These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30499059)

  • 21. A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects.
    Bildik HN; Esenboga S; Halaclı SO; Karaatmaca B; Aytekin ES; Nabiyeva N; Akarsu A; Ocak M; Erman B; Tan C; Arikoglu T; Yaz I; Cicek B; Tezcan I; Cagdas D
    Pediatr Allergy Immunol; 2024 Sep; 35(9):e14245. PubMed ID: 39312287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic characterization of patients with activated PI3Kδ syndrome 1 presenting with features of systemic lupus erythematosus.
    Wang Y; Yang Q; Chen X; Tang W; Zhou L; Chen Z; An Y; Zhang Z; Tang X; Zhao X
    Genes Dis; 2021 Nov; 8(6):907-917. PubMed ID: 34522717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
    Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
    J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunodeficiency due to a novel variant in PIK3CD: a case report.
    Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
    Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
    Liu H; Tang XL; Liu JR; Li HM; Zhao SY
    Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
    Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
    Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
    Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort.
    Oh J; Garabedian E; Fuleihan R; Cunningham-Rundles C
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):4095-4102. PubMed ID: 34352450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1.
    Okano T; Imai K; Tsujita Y; Mitsuiki N; Yoshida K; Kamae C; Honma K; Mitsui-Sekinaka K; Sekinaka Y; Kato T; Hanabusa K; Endo E; Takashima T; Hiroki H; Yeh TW; Tanaka K; Nagahori M; Tsuge I; Bando Y; Iwasaki F; Shikama Y; Inoue M; Kimoto T; Moriguchi N; Yuza Y; Kaneko T; Suzuki K; Matsubara T; Maruo Y; Kunitsu T; Waragai T; Sano H; Hashimoto Y; Tasaki K; Suzuki O; Shirakawa T; Kato M; Uchiyama T; Ishimura M; Tauchi T; Yagasaki H; Jou ST; Yu HH; Kanegane H; Kracker S; Durandy A; Kojima D; Muramatsu H; Wada T; Inoue Y; Takada H; Kojima S; Ogawa S; Ohara O; Nonoyama S; Morio T
    J Allergy Clin Immunol; 2019 Jan; 143(1):266-275. PubMed ID: 29778502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
    Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
    J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
    Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
    Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
    Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
    Michalovich D; Nejentsev S
    Front Immunol; 2018; 9():369. PubMed ID: 29535736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
    Cohen JI
    Front Immunol; 2018; 9():237. PubMed ID: 29599765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
    Li GM; Liu HM; Guan WZ; Xu H; Wu BB; Feng JY; Sun L
    Medicine (Baltimore); 2019 May; 98(18):e15329. PubMed ID: 31045771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exhaustion of the CD8
    Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
    Front Immunol; 2018; 9():446. PubMed ID: 29563914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.
    Angulo I; Vadas O; Garçon F; Banham-Hall E; Plagnol V; Leahy TR; Baxendale H; Coulter T; Curtis J; Wu C; Blake-Palmer K; Perisic O; Smyth D; Maes M; Fiddler C; Juss J; Cilliers D; Markelj G; Chandra A; Farmer G; Kielkowska A; Clark J; Kracker S; Debré M; Picard C; Pellier I; Jabado N; Morris JA; Barcenas-Morales G; Fischer A; Stephens L; Hawkins P; Barrett JC; Abinun M; Clatworthy M; Durandy A; Doffinger R; Chilvers ER; Cant AJ; Kumararatne D; Okkenhaug K; Williams RL; Condliffe A; Nejentsev S
    Science; 2013 Nov; 342(6160):866-71. PubMed ID: 24136356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
    Diaz N; Juarez M; Cancrini C; Heeg M; Soler-Palacín P; Payne A; Johnston GI; Helmer E; Cain D; Mann J; Yuill D; Conti F; Di Cesare S; Ehl S; Garcia-Prat M; Maccari ME; Martín-Nalda A; Martínez-Gallo M; Moshous D; Santilli V; Semeraro M; Simonetti A; Suarez F; Cavazzana M; Kracker S
    J Immunol; 2020 Dec; 205(11):2979-2987. PubMed ID: 33115853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
    Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
    Front Immunol; 2019; 10():77. PubMed ID: 30891027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.